单位：浙江大学医学院附属第一医院

研究方向： 血液病

社会任职
长期从事恶性肿瘤和和细胞免疫治疗研究。参与编写了由人民卫生出版社出版的细胞免疫治疗专著《CAR-T细胞治疗学》和《CAR-T细胞免疫治疗100问》，在细胞免疫治疗领域，积极参与临床研究，推动CAR-T细胞治疗的临床应用，致力于提升治疗效果和患者生存质量，作为主要完成人，获得了浙江省科技进步一等奖（第八）及中华医学科技奖二等奖（第十）。相关工作以第一作者/共同第一作者发表在《Lancet Haematology》、《Journal of Hematology & Oncology》、《Clinical Cancer Research》、《Science China-Life Sciences》、《Britsh Journal of Haematology》等期刊发表SCI论文20余篇： [1]. Zhou L, Zhao Y, Zheng Y, et al. The Prognostic Value of the Number of Negative Lymph Nodes Combined with Positive Lymph Nodes in Esophageal Cancer Patients: A Propensity-Matched Analysis[J]. Ann Surg Oncol, 2020, 27 (6): 2042-2050. [2]. Wu Y, Zhou L, Deng Y, et al. The polymorphisms (rs3213801 and rs5744533) of DNA polymerase kappa gene are not related with glioma risk and prognosis: A case-control study[J]. Cancer Med, 2019, 8 (17): 7446-7453. [3]. Deng Y, Zhou L, Li N, et al. Impact of four lncRNA polymorphisms (rs2151280, rs7763881, rs1136410, and rs3787016) on glioma risk and prognosis: A case-control study[J]. Mol Carcinog, 2019, 58 (12): 2218-2229. [4]. Zhou L, Dong S, Deng Y, et al. GOLGA7 rs11337, a Polymorphism at the MicroRNA Binding Site, Is Associated with Glioma Prognosis[J]. Mol Ther Nucleic Acids, 2019, 18: 56-65. [5]. Zhou L, Deng Y, Li N, et al. Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study[J]. J Hematol Oncol, 2019, 12 (1): 107. [6]. Deng Y, Wang M, Zhou L, et al. Global burden of larynx cancer, 1990-2017: estimates from the global burden of disease 2017 study[J]. Aging (Albany NY), 2020, 12 (3): 2545-2583. [7]. Li N, Deng Y, Zhou L, et al. Global burden of breast cancer and attributable risk factors in 195 countries and territories, from 1990 to 2017: results from the Global Burden of Disease Study 2017[J]. J Hematol Oncol, 2019, 12 (1): 140. [8]. Zhou L, Yang P, Zheng Y, et al. Effects of Postoperative Radiotherapy in Early Breast Cancer Patients Older than 75 Years: A Propensity-Matched Analysis[J]. J Cancer, 2019, 10 (25): 6225-6232. [9]. Deng Y, Zhou L, Yao J, et al. Associations of lncRNA H19 Polymorphisms at MicroRNA Binding Sites with Glioma Susceptibility and Prognosis[J]. Mol Ther Nucleic Acids, 2020, 20: 86-96. [10]. Yao L, Zhou L, Deng Y, et al. Association Between Genetic Polymorphisms In TYMS And Glioma Risk In Chinese Patients: A Case-Control Study[J]. Onco Targets Ther, 2019, 12: 8241-8247. [11]. Zhou L, Dai C, Tian T, et al. Prognostic Values of LAPTM4B-35 in Human Cancer: A Meta-analysis[J]. J Cancer, 2018, 9 (23): 4355-4362. [12]. Zhou L, Zheng Y, Tian T, et al. Associations of interleukin-6 gene polymorphisms with cancer risk: Evidence based on 49,408 cancer cases and 61,790 controls[J]. Gene, 2018, 670: 136-147. [13]. Yi M, Zhou L, Li A, Luo S, Wu K. Global burden and trend of acute lymphoblastic leukemia from 1990 to 2017. Aging. 2020; 12: 22869-91. [14]. Li H, Zhou L, Ma J, Zhu Y, Fan J, Li N, et al. Distribution and susceptibility of ERCC1/XPF gene polymorphisms in Han and Uygur women with breast cancer in Xinjiang, China. Cancer medicine. 2020; 9: 9571-80. [15].Zhang M, Wei G, Zhou L, et al . GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol. 2023 Feb;10(2):e107-e116. [16]. Zhang M, Zhou L, Zhao H, et al. Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy. Clin Cancer Res. 2021 Dec 1;27(23):6384-6392. [17]. Zhou L, Feng Y, Hong R, et al. Integrating genomic features for prognosis in Chinese patients with B-cell lymphoma following chimeric antigen receptor T-cell therapy. Sci China Life Sci. 2025 Jun;68(6):1703-1713. [18]. Zhou L, Fu W, Wu S, et al. Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre study. Br J Haematol. 2023 Aug;202(3):517-524. [19]. Wang L, Hong R, Zhou L, et al. Cytokine profiles are associated with prolonged hematologic toxicities after B-cell maturation antigen targeted chimeric antigen receptor-T-cell therapy. Cytotherapy. 2023 Feb;25(2):192-201. [20]. Zhou L, Yu Q, Wei G, et al. Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. BMC Cancer. 2021 May 25;21(1):606. [21].Zhou L, Zhao H, Shao Y, , et al. Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment. J Cancer. 2021 Jul 13;12(18):5423-5431.

个人介绍
住院医师